Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
News

Jewish group sets bold goal to screen hundreds of thousands for genetic diseases

Since screening for Tay-Sachs began in the 1970s, the number of Ashkenazi Jews born with the rare inherited disease that destroys nerve cells in the brain and spinal cord has plummeted by 90 percent worldwide.

Now, JScreen, a non-profit organization associated with the Department of Genetics at Emory University in Atlanta, is trying to replicate those results as it screens for a whole host of other genetic diseases that are common in the Jewish community. The goal is to save couples the heartache of having a child born with one of those diseases.

To spotlight its efforts, the organization designated the first week in February as Jewish Genetic Screening Awareness Week and they are offering a discount to anyone registering for the screening this week. To apply for the genetic screening, applicants can complete the application on the JScreen.org website.

“Our goal is to screen hundreds of thousands of young people of reproductive age to save lives,” said Hillary Kener Regelmann, director of national outreach for JScreen.

Randy Gold and his wife, Caroline, had basic Jewish genetic testing done in 2004 before they had children. Their first child, Natanel, is a healthy boy. But their second child, Eden, was born with a rare genetic disease, Mucolipidosis type 1V (ML4). Among other things, the degenerative disease can lead to blindness, confinement to a wheelchair and a shortened life expectancy.

Randy and Caroline Gold with their daughter Eden at her Bat Mitzvah.

Randy and Caroline Gold with their daughter Eden at her Bat Mitzvah. Courtesy of Gold Family

The unexpected birth defect caused the Atlanta-based Golds to establish JScreen in 2013 to help others avoid the same pain they experienced. Supported by funding from the Marcus Foundation, JScreen not only checks for various diseases but has a genetic counselor discuss the results in-depth with each couple.

“We wanted to give other couples the information they need so that they could make an informed decision on how they want to build their family,” Randy Gold explained. “When you have information that indicates the two of you have the same mutation, you have a 25 percent chance of passing it along to your child. When you know you both have the same mutation, you can then decide whether you would be comfortable with any number of options – including taking your chances or terminating the pregnancy if you find the fetus has the disease. You could also adopt a child, use a sperm or egg donor or use in vitro fertilization [IVF] and pre-implantation genetic diagnosis [PGD].”

Gold said he and his wife went through four rounds of IVF and PGD, after which they gave birth to their third child, Shai, a healthy baby girl.

“There are many families that have reached out to us to express their thanks and appreciation for giving them the ability to have a healthy child or a healthy grandchild,” Gold said.

Goldie and Josh Grinberg decided to go through IVF, based on information they received from JScreen.

Goldie and Josh Grinberg decided to go through IVF, based on information they received from JScreen. Courtesy of Grinberg Family

One of them, Josh and Goldie Grinberg of Brighton, Mass., were married in 2017 and had genetic testing done by JScreen that found they were both carriers for Gaucher Disease, which is another common genetic disease in Ashekenazi Jews.

“That prompted our decision to do IVF so we could test the embryos,” Goldie, 24, said. They started the IVF process in 2019 and are still trying.

“There is a lot of uncertainty with IVF,” said Josh, 27. “Even though we may have an embryo with no genetic defects, there is no guarantee it will implant properly. We were told that with a healthy embryo there is only about a 70 percent chance of a live birth.”

But Goldie insisted: “We stand by our decision. It is worth the extra effort now rather than having a child with a disease that affects him his whole life.”

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you move on, I wanted to ask you to support the Forward’s award-winning journalism during our High Holiday Monthly Donor Drive.

If you’ve turned to the Forward in the past 12 months to better understand the world around you, we hope you will support us with a gift now. Your support has a direct impact, giving us the resources we need to report from Israel and around the U.S., across college campuses, and wherever there is news of importance to American Jews.

Make a monthly or one-time gift and support Jewish journalism throughout 5785. The first six months of your monthly gift will be matched for twice the investment in independent Jewish journalism. 

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.